FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 06, 2023 at 04:11 pm
Share
FibroGen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 40.13 million compared to USD 15.74 million a year ago. Net loss was USD 63.62 million compared to USD 91.65 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.98 a year ago.
For the nine months, revenue was USD 120.61 million compared to USD 106.37 million a year ago. Net loss was USD 228 million compared to USD 227.48 million a year ago. Basic loss per share from continuing operations was USD 2.35 compared to USD 2.43 a year ago.
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.